Source comparison
Comparison Table: CJC-1295 No DAC & Ipamorelin Biomarkers
Serum IGF-1 115–307 ng/mL (age-dependent) +15–50% from baseline within 4–6 weeks Fasting, 8–10 AM, 4–6 weeks post-initiation Reflects chronic GH axis activity; values 400 ng/mL suggest supraphysiological stimulation Fasting G
This comparison does not assign a generated winner or score.
- Serum IGF-1
- 115–307 ng/mL (age-dependent)
- +15–50% from baseline within 4–6 weeks
- Fasting, 8–10 AM, 4–6 weeks post-initiation
- Reflects chronic GH axis activity; values <180 ng/mL suggest poor response, >400 ng/mL suggest supraphysiological stimulation
- Fasting Glucose
- 70–99 mg/dL
- May rise 5–15 mg/dL transiently
- Fasting, 8–10 AM, baseline and every 8–12 weeks
- GH's counter-regulatory effect on insulin; sustained elevation >110 mg/dL warrants dose reduction
- HbA1c
- <5.7%
- Should remain stable; monitor if trending upward
- Baseline and every 12 weeks
- 3-month glucose average; values approaching 6.0% indicate excessive GH-induced insulin resistance
- Triglycerides
- <150 mg/dL
- Decrease 10–25% by week 8–12
- Fasting, baseline and every 8–12 weeks
- Confirms enhanced lipolysis; failure to drop suggests inadequate dosing or poor dietary adherence
- LDL-C
- <130 mg/dL optimal
- May rise transiently weeks 1–6, should normalise by week 8–10
- Transient rise reflects lipid mobilisation; sustained elevation >160 mg/dL indicates lipid clearance issue
- IGFBP-3
- 3.5–7.0 mg/L
- Should track proportionally with IGF-1
- Same draw as IGF-1
- Secondary GH axis marker; IGF-1/IGFBP-3 ratio outside 0.15–0.4 flags GH resistance or hypersecretion